1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,004 | 0,018 | 17:38 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aptamer Group PLC - Trading update - Media comment and speculation | - | RNS | ||
| Mi | Aptamer shares slide despite revenue improvement | 1 | Sharecast | ||
| Mi | TRADING UPDATES: EnSilica hails "solid" half-year; Aptamer revenue up | 3 | Alliance News | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| Mi | Aptamer Group PLC - Half Year Trading Update | 1 | RNS | ||
| 23.12.25 | IN BRIEF: Aptamer signs Optimer contract with US biotech Alphazyme | 1 | Alliance News | ||
| 23.12.25 | Aptamer Group inks Optimer licensing agreement with Alphazyme | 2 | Sharecast | ||
| 23.12.25 | Aptamer Group PLC - Aptamer signs licensing agreement with Alphazyme | - | RNS | ||
| 16.12.25 | Aptamer Group signs licensing deal with Twist Bioscience for NGS market | 2 | Investing.com | ||
| 16.12.25 | Aptamer Group schließt Lizenzabkommen mit Twist Bioscience für den NGS-Markt | 6 | Investing.com Deutsch | ||
| 16.12.25 | Aptamer Group PLC - Licensing agreement with Twist Bioscience | 1 | RNS | ||
| 27.11.25 | Aptamer enters new financial year with growing commercial momentum | 2 | Sharecast | ||
| 27.11.25 | Aptamer Group PLC - Results of 2025 Annual General Meeting | - | RNS | ||
| 27.11.25 | Aptamer Group PLC - AGM Statement | 1 | RNS | ||
| 14.11.25 | Aptamer grows order book with two new pharma contracts | 2 | Sharecast | ||
| 14.11.25 | Aptamer hails two "key" contract wins; eyes revenue to beat prior year | 1 | Alliance News | ||
| 14.11.25 | Aptamer Group PLC - Strong contract wins build commercial momentum | - | RNS | ||
| 04.11.25 | Aptamer signs contract with 'top five' pharma client | 1 | Sharecast | ||
| 04.11.25 | IN BRIEF: Aptamer hails new contract with "top 5 pharma company" | 1 | Alliance News | ||
| 04.11.25 | AIM WINNERS & LOSERS: Aptamer wins contract; Image Scan swings to loss | 3 | Alliance News | ||
| 04.11.25 | Aptamer Group PLC - New contract with top five pharma company | 1 | RNS |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIODESIX | 7,890 | +44,51 % | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 35,000 | +27,04 % | Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition | Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA)... ► Artikel lesen | |
| QIAGEN | 40,910 | -0,78 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,340 | -11,89 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 4,840 | +3,86 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 10,620 | +18,79 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| BIONTECH | 86,10 | +0,23 % | BioNTech-Aktie: Ein guter Kauf für 2026? | Seit Anfang Dezember 2025 tritt die BioNTech-Aktie bei Kursen um die 96 US$ auf der Stelle. Auch zum Jahresstart zeigt sie wenig Bewegung. Sehen Anleger hier keine guten Investmentchancen für 2026?... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 17,390 | -6,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 55,08 | +1,62 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| ABIVAX | 103,60 | +4,86 % | Abivax: NBC-Volltreffer explodiert erneut - wird die Übernahme jetzt besiegelt? | Der US-Pharmakonzern Eli Lilly prüft eine der größten Übernahmen im europäischen Biotechnologiesektor: Rund 15 Milliarden Euro könnte demnach der Kauf der französischen Biotech-Gesellschaft Abivax kosten.... ► Artikel lesen | |
| EVOTEC | 6,482 | +3,12 % | Evotec Aktie: Das große Comeback im Jahr 2026? | Nächster Anlauf der Evotec Aktie auf große charttechnische Kaufsignale - bisher misslangen diese Ausbruchsversuche. Nachdem die Biotech-Aktie in den letzten Tagen zunächst an der Unterstützung bei 5... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,485 | -6,15 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| ALUMIS | 20,135 | +2,94 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 275,15 | -4,61 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 7,450 | -29,32 % | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy | LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants... ► Artikel lesen |
APTAMER GROUP PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,009 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.